Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE  
55.60
-0.17 (-0.30%)
Earnings Announcements

Ultragenyx Reports Second Quarter 2022 Financial Results And Corporate Update

Published: 07/28/2022 21:25 GMT
Ultragenyx Pharmaceutical Inc. (RARE) - Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update.
As of June 30, 2022, Cash, Cash Equivalents, and Marketable Debt Securities Were $706.1 Million.
Continues to Expect 2022 Revenue for Crysvita in Ultragenyx Territories to Be Between $250 Million and $260 Million.
Continues to Expect 2022 Dojolvi Revenue to Be Between $55 Million and $65 Million.
Qtrly Net Loss per Share, Basic and Diluted $2.26.
Q2 Earnings per Share View $-1.75 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $96.2 Million
Adjusted EPS is expected to be -$1.30

Next Quarter Revenue Guidance is expected to be $105.77 Million
Next Quarter EPS Guidance is expected to be -$1.87

More details on our Analysts Page.